secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001437749-24-021083
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Therapeutics appoints Sarah Boyce to Board, effective June 24, 2024
-----------------------------------------------------------------------------

- Sarah Boyce appointed as Class I director and Chair of Nominating and Corporate Governance Committee.
- Boyce currently President & CEO of Avidity Biosciences (RNA); past roles include Akcea, Ionis, Forest Labs.
- As non-employee director, receives standard compensation including initial option for 29,500 Class A shares.
- Replaces Lori Lyons-Williams as Committee Chair; Lyons-Williams remains a member of the committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924021083/0001437749-24-021083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924021083/cont20240611_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-021083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer